A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

NCT02875678 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-09-07

No results posted yet for this study

Summary

A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients with Functional Dyspepsia.

Conditions

  • Dyspepsia

Interventions

DRUG

ABX-1431

Single-dose ABX-1431

DRUG

Placebo

Single-dose matching placebo

Sponsors & Collaborators

  • Abide Therapeutics

    lead INDUSTRY

Principal Investigators

  • Chan Beals, MD,PhD · Abide Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-22
Primary Completion
2017-08-07
Completion
2017-08-07

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02875678 on ClinicalTrials.gov